Guided Therapeutics (GTHP) Cash from Operations Growth (1y) (2017 - 2025)
Guided Therapeutics (GTHP) Cash from Operations Growth (1y) (2017 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 183.47 Bn | 176.17 Bn | 6.27 Bn | -7.20% |
| 2 | Stryker | 128.89 Bn | 126.01 Bn | 3.81 Bn | 132.40% |
| 3 | Medtronic | 108.71 Bn | 99.49 Bn | 6.41 Bn | 1.78% |
| 4 | Boston Scientific | 68.50 Bn | 67.05 Bn | 3.61 Bn | -35.67% |
| 5 | Edwards Lifesciences | 48.59 Bn | 44.92 Bn | 1.29 Bn | -84.38% |
| 6 | Dexcom | 28.40 Bn | 27.29 Bn | 750.30 Mn | 185.96% |
| 7 | GE HealthCare Technologies | 28.34 Bn | 26.06 Bn | 1.98 Bn | 16.00% |
| 8 | Smith & Nephew | 26.93 Bn | 26.35 Bn | - | - |
| 9 | Koninklijke Philips | 25.50 Bn | 22.37 Bn | 2.07 Bn | 122.43% |
| 10 | Guided Therapeutics | 20.39 Mn | 20.32 Mn | 458,000.00 | 12.35% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 12.35% |
| Sep 30, 2025 | 41.44% |
| Jun 30, 2025 | 21.03% |
| Mar 31, 2025 | -231.00% |
| Dec 31, 2024 | 1.19% |
| Sep 30, 2024 | 0.00% |
| Jun 30, 2024 | 51.14% |
| Mar 31, 2024 | 79.96% |
| Dec 31, 2023 | 0.88% |
| Sep 30, 2023 | 22.71% |
| Jun 30, 2023 | -25.50% |
| Mar 31, 2023 | -178.77% |
| Dec 31, 2022 | -313.21% |
| Sep 30, 2022 | 17.19% |
| Jun 30, 2022 | 49.57% |
| Mar 31, 2022 | 44.06% |
| Dec 31, 2021 | 148.04% |
| Sep 30, 2021 | -21.95% |
| Jun 30, 2021 | -69.61% |
| Mar 31, 2021 | 39.62% |